Furthermore, several evidence suggests that AXL overexpression drives wide-ranging processes: epithelial to mesenchymal transition, angiogenesis, resistance to chemotherapic and targeted agents, and decreased anti-tumor immune response [38]. This evidence concerns the gene AXL and neoplasm.